Home
Home
Contact
Careers
Terms and Conditions
Privacy Policy
Cookie Policy
YouTube
X
LinkedIn
About Arcturus
RNA Medicines
Technologies
Pipeline
Clinical Trials
Business Development
Publications
Investor Relations

Immunogenicity and safety of self-amplifying mRNA COVID-19 vaccine (ARCT-2303), with or without co-administration of seasonal inactivated influenza vaccine in adults: a phase 3, randomised, controlled, observer-blind, multicentre study

August 22, 2025

Home
Contact
Careers
Terms and Conditions
Privacy Policy
Cookie Policy
YouTube
X
LinkedIn
© 2026 Arcturus Therapeutics, Inc.